3,782 results found
    1. Evolutionary Biology
    2. Cancer Biology

    Evolutionary dynamics of cancer in response to targeted combination therapy

    Ivana Bozic et al.
    A study that models the evolution of drug resistance in tumors reveals that drugs are more effective when given in combination than sequentially, and that cure is much more likely when the drugs target different pathways.
    1. Biochemistry and Chemical Biology
    2. Cancer Biology

    Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy

    Alexander A Warkentin et al.
    Anti-targets are proteins that cause problems when inhibited along with an intended target and our novel chemical strategy affords unprecedented selectivity in the context of FLT3 vs. KIT inhibition for treatment of a devastating blood cancer.
    1. Cancer Biology

    Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer

    Laura Cato et al.
    Targeting the activation of the androgen receptor N-terminal domain by the cochaperone Bag-1L provides a new approach for inhibiting androgen receptor function to treat prostate cancer.
    1. Cancer Biology
    2. Developmental Biology

    Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

    Carla S Verissimo et al.
    Libraries of patient-derived tumor organoids are a reliable and scalable model system that can help identify and optimize targeted therapies in a pre-clinical setting.
    1. Cell Biology
    2. Cancer Biology

    MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells

    Yubao Wang et al.
    Maternal embryonic leucine zipper kinase (MELK) is a new anti-cancer target that is highly selective for basal-like breast cancer.
    1. Cancer Biology

    Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

    S Michael Rothenberg et al.
    SOX2 causes resistance to anti-EGFR therapies in EGFR-mutant lung cancer.
    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics

    Genome-wide dynamics of Pol II elongation and its interplay with promoter proximal pausing, chromatin, and exons

    Iris Jonkers et al.
    The elongation rate of RNA Polymerase II varies greatly between and along genes, as this enzyme accelerates from stable pausing to rapid elongation within genes, and is influenced by CG-content, exons and chromatin.
    1. Structural Biology and Molecular Biophysics

    KCNE1 tunes the sensitivity of KV7.1 to polyunsaturated fatty acids by moving turret residues close to the binding site

    Johan E Larsson et al.
    An auxiliary subunit alters the effect of a family of small-molecule openers on a voltage-gated potassium channel by inducing structural re-arrangements that promote protonation of the drug molecule.
    1. Cancer Biology
    2. Chromosomes and Gene Expression

    Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance

    Rachel W Anantha et al.
    Systematic analyses of natural variants and artificial mutants establish functional landscapes of BRCA1 for homology-directed repair (HDR) and therapy resistance and identify the BRCA1-PALB2 interaction as a key control point for HDR pathway choice.

Refine your results by:

Type
Research categories